PICO Portalanswers from OpenAlex & ORCID
Carlos L. Arteaga
ResearcherPublications, citations & collaboration network
Carlos L. Arteaga is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does Carlos L. Arteaga have?
PICO Portalindexed works
Carlos L. Arteaga has 1,327 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Carlos L. Arteaga have?
PICO Portalcitation count
Carlos L. Arteaga has 56,280 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of Carlos L. Arteaga?
PICO Portalh-index
Carlos L. Arteaga has an h-index of 124 in OpenAlex.
What is the i10-index of Carlos L. Arteaga?
PICO Portali10-index
Carlos L. Arteaga has an i10-index of 393 in OpenAlex.
What is the ORCID of Carlos L. Arteaga?
PICO Portalorcid
The ORCID for Carlos L. Arteaga is on the source record.
What is the OpenAlex record for Carlos L. Arteaga?
PICO Portalopenalex
The OpenAlex for Carlos L. Arteaga is on the source record.
What are the most-cited papers on Carlos L. Arteaga?
PICO Portalmost cited works
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch–Shimon, Mario Campone, Kimberly Blackwell, Fabrice André, Eric P. Winer, Wolfgang Janni, Sunil Verma, PierFranco Conte, Carlos L. Arteaga, David Cameron, Katarína Petráková, Lowell L. Hart, Cristian Villanueva, Arlene Chan, Erik Jakobsen, Arnd Nusch, Olga Burdaeva, Eva‐Maria Grischke, Emilio Alba, Erik Wist, Norbert Marschner, Anne Favret, Denise A. Yardley, Thomas Bachelot, Ling-Ming Tseng, Sibel Blau, Fengjuan Xuan, Farida Souami, Michelle C. Miller, Caroline Germa, Samit Hirawat, Joyce O’Shaughnessy
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
Gabriel N. Hortobágyi, Salomon M. Stemmer, H. A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch–Shimon, Mario Campone, Katarína Petráková, Kim T. Blackwell, Eric P. Winer, W Janni, S. Verma, PierFranco Conte, Carlos L. Arteaga, David Cameron, S. Mondal, Faye Su, Marshall G. Miller, Mohamed Elmeliegy, Caroline Germa, Joyce O’Shaughnessy
BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors
Anthony C. Faber, Ryan B. Corcoran, Hiromichi Ebi, Lecia V. Sequist, Belinda A. Waltman, Euiheon Chung, João Incio, Subba R. Digumarthy, Sarah F. Pollack, Youngchul Song, Alona Muzikansky, Eugene Lifshits, Sylvie Roberge, Erik J. Coffman, Cyril H. Benes, Henry Gómez, José Baselga, Carlos L. Arteaga, Miguel N. Rivera, Dora Dias‐Santagata, Rakesh K. Jain, Jeffrey A. Engelman